The recruitment and retention of qualified patients can be challenging: 

— 94% of patients don’t have access to clinical trials*

— 1 in 4 patients drop out before study completion* 

— 78% of patients would find it helpful if IMP were delivered to their home**

However, moving some trial site activities into patients’ homes has been shown to increase recruitment by 60% or more, and typically maintains patient retention at over 95%*. That means Direct to Patient models can help bring your product to market faster, minimize disruptions to patients' lives and expand patient access to the best possible treatment options at home. There are also beneficial Direct to Patient applications for commercial drug home distribution programs, patient sample collections and returns. 

*Medical Research Network

**International Society for Pharmaceutical Engineering

Our collaboration offers an integrated clinical trial supply chain that improves the quality and accountability in the transport, storage and dispensing of products while maximising recruitment and retention in clinical trials.